MedTrace Logo

Response Prediction in EBV-HLH Using Metabonomics Analysis

NCT05677178 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-01-10

No results posted yet for this study

Summary

Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal. Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals. We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets.

Conditions

  • Hemophagocytic Lymphohistiocytoses
  • EBV
  • Metabonomics

Interventions

OTHER

observational

This study is an observational study without any intervention.

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • Zhao Wang, MD · Beijing Friendship Hospital

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-12-01
Completion
2025-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05677178 on ClinicalTrials.gov